EyePoint (EYPT) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
X4 Pharmaceuticals (XFOR) has outperformed EyePoint (EYPT) over the past year, losing 16.0% versus a loss of 75.1%. Over five years, EYPT leads with a -69.8% price change compared with -98.2% for XFOR. EyePoint is the larger company by market cap ($290.1 million vs $276.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EYPT | XFOR |
|---|---|---|
| Share price | $3.46 | $2.79 |
| Market cap | $290.09M | $276.62M |
| 1-day change | +4.22% | -0.71% |
| YTD return | -81.06% | -30.25% |
| 1-year return | -75.07% | -15.96% |
| 5-year return | -69.76% | -98.22% |
| P/E ratio (TTM) | — | 139.50 |
| EPS (TTM) | $-3.90 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.11 | $4.83 |
| 52-week low | $3.05 | $2.70 |
| Distance from 52-week high | -81.89% | -42.24% |
| Analyst consensus | none | none |
| Avg. price target upside | +648.84% | +315.77% |
| Average volume | 3.96M | 849.58K |
| Shares outstanding | 83.84M | 99.15M |
| Employees | 214 | 45 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XFOR has outperformed EYPT by 59.1 percentage points over the past year.
- The two companies sit in different sectors: EyePoint in Industrials and X4 Pharmaceuticals in Health Care.
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
EYPT vs XFOR FAQ
Which is bigger, EyePoint or X4 Pharmaceuticals?
EyePoint (EYPT) is larger, with a market capitalization of $290.09M compared with $276.62M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, EYPT or XFOR?
XFOR returned -15.96% over the past 12 months, compared with -75.07% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are EyePoint and X4 Pharmaceuticals in the same industry?
No. EyePoint is in the Industrials sector, while X4 Pharmaceuticals is in Health Care.